Gene | Score gda | Association Type | Type | Original DB | Sentence supporting the association | PMID | PMID Year | ||||
---|---|---|---|---|---|---|---|---|---|---|---|
|
0.100 | GeneticVariation | disease | BEFREE | The present meta-analysis demonstrates that CYP2C19 RMs with RE have an increased risk of being refractory to PPI therapy compared with PMs. | 26580676 | 2016 | ||||
|
0.100 | GeneticVariation | disease | BEFREE | The CYP2C19 genotype may influence the therapeutic effect of PPI for reflux esophagitis. | 25910560 | 2015 | ||||
|
0.100 | GeneticVariation | disease | BEFREE | CYP2C19 genotypes determine the efficacy of on-demand therapy of pantoprazole for reflux esophagitis as Los-Angeles grades C and D. | 21777277 | 2012 | ||||
|
0.100 | GeneticVariation | disease | BEFREE | We investigated the effect of CYP2C19 gene polymorphisms on the clinical response to treatment with omeprazole in Iranian patients with erosive reflux esophagitis. | 20804307 | 2010 | ||||
|
0.100 | GeneticVariation | disease | BEFREE | CYP2C19 genetic polymorphism also affects the therapeutic outcome of gastroesophageal reflux disease (GERD), reflux oesophagitis and duodenal ulcers. | 18765869 | 2008 | ||||
|
0.100 | GeneticVariation | disease | BEFREE | This study assessed the endoscopic healing rates of reflux esophagitis with Los Angeles grades C and D (RE-CD) using a 6-month esomeprazole and the demographic factors or genotypes of S-mephenytoin 4'-hydroxylase (CYP2C19) that correlated with the healing of RE-CD. | 18702650 | 2008 | ||||
|
0.100 | GeneticVariation | disease | BEFREE | Cytochrome P450 2C19 polymorphism influences the preventive effect of lansoprazole on the recurrence of erosive reflux esophagitis. | 17295875 | 2007 | ||||
|
0.100 | GeneticVariation | disease | BEFREE | The present study was designed to investigate whether the CYP2C19 genotype is related to the healing of reflux esophagitis (RE) in treatment with RPZ 10 mg. | 16911688 | 2006 | ||||
|
0.100 | Biomarker | disease | BEFREE | A total of 119 Japanese patients with recurrent reflux oesophagitis underwent cytochrome P450 2C19 genotyping prior to receiving daily omeprazole 10 mg or 20 mg for 6-12 months, during which adverse event frequency, serum gastrin levels and endoscopic findings were monitored. | 15932363 | 2005 | ||||
|
0.100 | GeneticVariation | disease | BEFREE | The therapeutic effect of lansoprazole on erosive reflux oesophagitis is influenced by the CYP2C19 genotype status. | 12656699 | 2003 |